Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 2
1976 1
1977 1
1978 1
1985 1
1986 1
1987 1
1989 1
1990 1
1992 2
1994 1
1995 4
1996 1
1997 1
1998 1
1999 1
2000 1
2001 1
2003 1
2009 2
2019 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
Discovery of the Migraine Prevention Therapeutic Aimovig (Erenumab), the First FDA-Approved Antibody against a G-Protein-Coupled Receptor.
King CT, Gegg CV, Hu SN, Sen Lu H, Chan BM, Berry KA, Brankow DW, Boone TJ, Kezunovic N, Kelley MR, Shi L, Xu C. King CT, et al. Among authors: brankow dw. ACS Pharmacol Transl Sci. 2019 Sep 3;2(6):485-490. doi: 10.1021/acsptsci.9b00061. eCollection 2019 Dec 13. ACS Pharmacol Transl Sci. 2019. PMID: 32259079 Free PMC article.
NDF/heregulin stimulates the phosphorylation of Her3/erbB3.
Kita YA, Barff J, Luo Y, Wen D, Brankow D, Hu S, Liu N, Prigent SA, Gullick WJ, Nicolson M. Kita YA, et al. Among authors: brankow d. FEBS Lett. 1994 Jul 25;349(1):139-43. doi: 10.1016/0014-5793(94)00644-x. FEBS Lett. 1994. PMID: 8045292 Free article.
T-cell co-stimulation through B7RP-1 and ICOS.
Yoshinaga SK, Whoriskey JS, Khare SD, Sarmiento U, Guo J, Horan T, Shih G, Zhang M, Coccia MA, Kohno T, Tafuri-Bladt A, Brankow D, Campbell P, Chang D, Chiu L, Dai T, Duncan G, Elliott GS, Hui A, McCabe SM, Scully S, Shahinian A, Shaklee CL, Van G, Mak TW, Senaldi G. Yoshinaga SK, et al. Among authors: brankow d. Nature. 1999 Dec 16;402(6763):827-32. doi: 10.1038/45582. Nature. 1999. PMID: 10617205
Enhancement of therapeutic protein in vivo activities through glycoengineering.
Elliott S, Lorenzini T, Asher S, Aoki K, Brankow D, Buck L, Busse L, Chang D, Fuller J, Grant J, Hernday N, Hokum M, Hu S, Knudten A, Levin N, Komorowski R, Martin F, Navarro R, Osslund T, Rogers G, Rogers N, Trail G, Egrie J. Elliott S, et al. Among authors: brankow d. Nat Biotechnol. 2003 Apr;21(4):414-21. doi: 10.1038/nbt799. Epub 2003 Mar 3. Nat Biotechnol. 2003. PMID: 12612588
An antibody to IP-10 is a potent antagonist of cell migration in vitro and in vivo and does not affect disease in several animal models of inflammation.
Byrne FR, Winters A, Brankow D, Hu S, Juan T, Steavenson S, Doellgast G, Kuchimanchi K, Brown H, Anderson S, Smelt S, Sullivan T, Alcorn D, Tocker J, Dean C Jr, Macmaster J, Kirchner J, Buys J, Manoukian R, Jiao E, Zou X, Campanella GS, Siu G. Byrne FR, et al. Among authors: brankow d. Autoimmunity. 2009 Mar;42(3):171-82. doi: 10.1080/08916930802629547. Autoimmunity. 2009. PMID: 19301198
27 results